NHS Grampian
Formulary Group Decisions for SMC advice published April 2015 to March 2018

This document summarises the decisions of the NHS Grampian Formulary Group for Scottish Medicines Consortium (SMC) advice published April 2015 to March 2018.

For the latest Formulary Group decisions see the Grampian Area Formulary website.

August 2023

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
5-aminolaevulinic acid (as hydrochloride) 78mg/g gel (Ameluz®)	1260/17	Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults.	Routinely available in line with local guidance, Updates decision 20/02/18	21/01/2020
abatacept 125mg solution for injection in pre-filled syringe, pre-filled pen, 250mg powder for concentrate for solution for infusion (Orencia®)	1287/17	Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.	Not routinely available as not recommended for use in NHS Scotland, SMC 1287/17 https://www.scottishmedicines.org.uk/media/3089/abatacept_orencia_non_sub_final_oct_2017_for_website.pdf	21/11/2017
abatacept 125mg solution for injection pre-filled syringe, pre-filled pen, 250mg powder for concentrate for solution for infusion (Orencia®)	1230/17	Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.	Not routinely available as not recommended for use in NHS Scotland, SMC 1230/17 https://www.scottishmedicines.org.uk/media/1180/abatacept_orencia_non_sub_final_feb_2017_for_website.pdf	21/03/2017
abiraterone acetate 250mg tablets (Zytiga®)	873/13	In combination with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	Included on the Grampian Joint Formulary for the indication in question; restricted use. The 250mg tablet was discontinued 31 August 2017, replaced by a 500mg strength tablet. Updates decision 20/10/15	17/11/2015
adalimumab 40mg solution for injection in pre-filled syringe or pen, 40mg/0.8mL solution for injection vial for paediatric use (Humira®)	1050/15	For the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. **SMC restriction:** use within specialist rheumatology services (including those working within the network for paediatric rheumatology).	Included on the Grampian Joint Formulary for the indication in question; restricted use, Advice superseded by NICE TA373 Updates decision 19/05/15	19/01/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
adalimumab 40mg solution for injection in pre-filled syringe or pen, 40mg/0.8mL solution for injection vial for paediatric use (Humira®)	1068/15	Treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. **SMC restriction:** patients with severe disease as defined by a total Psoriasis Area Severity Index (PASI) score of ≥10 and a Dermatology Life Quality Index (DLQI) of >10.	Routinely available in line with national guidance, Advice superseded by NICE TA455 Updates decision 21/07/15	18/07/2017
adalimumab 40mg/0.4mL pre-filled syringe, pre-filled pen, 40mg/0.8mL vial for paediatric use (Humira®)	1243/17	Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.	Routinely available in line with national guidance, SMC 1243/17 https://www.scottishmedicines.org.uk/media/1195/adalimumab_humira_abbreviated_final_may_2017_for_website.pdf	20/06/2017
adalimumab 40mg/0.4mL pre-filled syringe, pre-filled pen, 40mg/0.8mL vial for paediatric use (Humira®)	1305/18	Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.	Not routinely available as not recommended for use in NHS Scotland, SMC 1305/18 https://www.scottishmedicines.org.uk/media/3090/adalimumab_humira_non_sub_final_dec_2017_for_website.pdf	16/01/2018
adalimumab 40mg/0.4mL, 40mg/0.8mL pre-filled syringe, pre-filled pen (Humira®)	1173/16	Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08)).	Not routinely available as not recommended for use in NHS Scotland, SMC 1173/16 https://www.scottishmedicines.org.uk/media/1192/adalimumab_humira_non_sub_final_june_2016_for_website.pdf	19/07/2016
adalimumab 40mg/0.4mL, 40mg/0.8mL pre-filled syringe, pre-filled pen (Humira®)	1209/16	Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.	Not routinely available as not recommended for use in NHS Scotland, SMC 1209/16 https://www.scottishmedicines.org.uk/media/1194/adalimumab_humira_non_sub_no_120916_final_oct_2016_for_website.pdf	15/11/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
adalimumab 40mg/0.4mL, 40mg/0.8mL pre-filled syringe, pre-filled pen, 40mg/0.8mL vial for paediatric use (Humira®)	1208/16	Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.	Not routinely available as not recommended for use in NHS Scotland, SMC 1208/16 https://www.scottishmedicines.org.uk/media/1193/adalimumab_humira_non_sub_no_120816_final_oct_2016_for_website.pdf	15/11/2016
adalimumab 40mg/0.8mL solution for injection (Humira®)	1143/16	For the treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.	Routinely available in line with national guidance, SMC 1143/16 https://www.scottishmedicines.org.uk/media/1191/adalimumab__humira__final_april_2016_for_website.pdf Updates decision 17/05/16	18/10/2016
afatinib 20mg, 30mg, 40mg, 50mg film-coated tablets (Giotrif®)	1174/16	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1174/16 https://www.scottishmedicines.org.uk/media/1212/afatinib_giotrif_non_sub_final_june_2016_for_website.pdf	19/07/2016
aflibercept 40mg/mL solution for injection (Eylea®)	1074/15	For adults for the treatment of visual impairment due to macular oedema secondary to branch retinal vein occlusion.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 15/09/15	17/11/2015
aflibercept 40mg/mL solution for injection (Eylea®)	1186/16	For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).	Routinely available in line with national guidance, SMC 1186/16 https://www.scottishmedicines.org.uk/media/1216/aflibercept_eylea_final_sept_2016_for_website.pdf Updates decision 18/10/16	21/02/2017
Akynzeo® 300mg/0.5mg hard capsules (netupitant/palonosetron)	1109/15	In adults for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 19/01/16	21/06/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
albiglutide 30mg, 50mg pre-filled pen (Eperzan®)	1024/15	Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.	This medicine is now withdrawn from use/discontinued, Updates decision 19/01/16	21/11/2017
alectinib hydrochloride 150mg hard capsules (Alecensa®)	1257/17	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.	Not routinely available as not recommended for use in NHS Scotland, SMC 1257/17 https://www.scottishmedicines.org.uk/media/1223/alectinib_hydrochloride_alecensa_non_sub_final_april_2017_for_website.pdf	20/06/2017
alendronic acid 70mg effervescent tablets (Binosto®)	1137/16	For the treatment of postmenopausal osteoporosis. **SMC restriction:** for use in patients who are unable to swallow tablets where alendronic acid is the appropriate treatment choice.	Not routinely available as there is a local preference for alternative medicines	19/04/2016
alirocumab 75mg, 150mg solution for injection in pre-filled pen (Praluent®)	1147/16	**SMC restriction:** for specialist use only in patients at high cardiovascular risk as follows: - patients with heterozygous familial hypercholesterolaemia (HeFH) and LDL-C ≥5.0mmol/L, for primary prevention of cardiovascular events or, - patients with HeFH and LDL-C ≥3.5mmol/L, for secondary prevention of cardiovascular events or, - patients at high risk due to previous cardiovascular events and LDL-C ≥4.0mmol/L or, - patients with recurrent/polyvascular disease and LDL-C ≥3.5mmol/L.	Routinely available in line with national guidance, SMC 1147/16 https://www.scottishmedicines.org.uk/media/1228/alirocumab_praluent_final_july_2016_amended_040816_for_website.pdf Updates decision 16/08/16	15/11/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
anakinra 100mg solution for injection in a pre-filled syringe (Kineret®)	1116/15	Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above, including: - Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA) - Muckle-Wells Syndrome (MWS) - Familial Cold Autoinflammatory Syndrome (FCAS)	Not recommended for use within NHS Scotland	15/12/2015
apremilast 10mg, 20mg, 30mg film-coated tablets (Otezla®)	1052/15	For the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 16/06/15	18/08/2015
apremilast 10mg, 20mg, 30mg film-coated tablets (Otezla®)	1053/15	Alone or in combination with disease modifying anti-rheumatic drugs (DMARDs), for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy. **SMC restriction:** for use in adult patients with active PsA who have had an inadequate response with at least two prior DMARD therapies or who are intolerant to such therapies.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 16/06/15	18/08/2015
aprepitant 80mg, 125mg hard capsules, 125mg powder for oral suspension (Emend®)	1241/17	As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).	Routinely available in line with national guidance, SMC 1241/17 https://www.scottishmedicines.org.uk/media/1256/aprepitant_emend_final_may_2017_amended_060617_for_website.pdf Updates decision 20/06/17	19/12/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
aprepitant 80mg, 125mg hard capsules, 125mg powder for oral suspension (Emend®)	1252/17	As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).	Routinely available in line with national guidance, SMC 1252/17 https://www.scottishmedicines.org.uk/media/1257/aprepitant_emend_abbreviated_final_june_2017_for_website.pdf Updates decision 18/07/17	19/12/2017
atomoxetine oral solution 4mg/mL (Strattera®)	1107/15	Treatment of attention-deficit/hyperactivity disorder in children of 6 years and older and in adolescents as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist. Diagnosis should be made according to current DSM criteria or the guidelines in ICD. **SMC restriction:** to use in patients who are unable to swallow capsules.	Included on the Grampian Joint Formulary for the indication in question; restricted use	15/12/2015
avanafil 50mg, 100mg, 200mg tablets (Spedra®)	980/14	Treatment of erectile dysfunction (ED) in adult men. In order for avanafil to be effective, sexual stimulation is required.	Not recommended for use within NHS Scotland	15/09/2015
azacitidine 25mg/mL powder for suspension for injection (Vidaza®)	1175/16	Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.	Not routinely available as not recommended for use in NHS Scotland, SMC 1175/16 https://www.scottishmedicines.org.uk/media/1285/azacitidine_vidaza_non_sub_final_june_2016_for_website.pdf	19/07/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
baricitinib 2mg, 4mg film-coated tablets (Olumiant®)	1265/17	Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate. **SMC restriction:** in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs. In patients with severe disease inadequately controlled by a TNF antagonist, it may be used in patients ineligible to receive rituximab.	Routinely available in line with national guidance, SMC 1265/17 https://www.scottishmedicines.org.uk/media/1294/baricitinib_olumiant_final_august_2017_amended_030916_for_website.pdf Updates decision 19/09/17	21/11/2017
belimumab 120mg, 400mg powder for concentrate for solution for infusion (Benlysta®)	775/12	Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy. **SMC restriction**: patients with evidence of serological disease activity (i.e. positive anti-dsDNA and low complement) and a Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score ≥10.	Routinely available in line with national guidance, SMC 775/12 https://www.scottishmedicines.org.uk/media/1301/belimumab_benlysta_resub_final_april_2017_for_website.pdf Updates decision 20/06/17	15/08/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®)	1063/15	In combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents. **SMC restriction:** to use in combination with paclitaxel.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 15/09/15	16/02/2016
bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®)	1135/16	In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. **SMC restriction:** for use in combination with cisplatin and paclitaxel	Routinely available in line with national guidance, SMC 1135/16 https://www.scottishmedicines.org.uk/media/1317/bevacizumab__avastin__final_april_2016_for_website.pdf Updates decision 17/05/16	18/10/2016
bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®)	1190/16	In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.	Not routinely available as not recommended for use in NHS Scotland, SMC 1190/16 https://www.scottishmedicines.org.uk/media/1318/bevacizumab_avastin_non_sub_final_august_2016_for_website.pdf	20/09/2016
bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®)	1275/17	In combination with carboplatin and paclitaxel for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.	Not routinely available as not recommended for use in NHS Scotland, SMC 1275/17 https://www.scottishmedicines.org.uk/media/1319/bevacizumab_avastin_non_sub_final_august_2017_for_website.pdf	19/09/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
bevacizumab 25mg/mL concentrate for solution for infusion (Avastin®)	806/12	In combination with carboplatin and paclitaxel, for the front-line treatment of advanced (International Federation of Gynaecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. **SMC restriction:** in patients with FIGO stage IV disease	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 17/11/15	16/02/2016
bezlotoxumab 25mg/mL concentrate for solution for infusion (Zinplava®)	1293/17	Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.	Not routinely available as not recommended for use in NHS Scotland, SMC 1293/17 https://www.scottishmedicines.org.uk/media/3092/bezlotoxumab_zinplava_non_sub_final_nov_2017_for_website.pdf	19/12/2017
blinatumomab 38.5micrograms powder for concentrate and solution for infusion (Blincyto®)	1145/16	The treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).	Routinely available in line with national guidance, SMC 1145/16 https://www.scottishmedicines.org.uk/media/1340/dad_blinatumomab_blincyto_final_may_2016_for_website.pdf Updates decision 21/06/16	15/08/2017
bortezomib 3.5mg powder for solution for injection (Velcade®)	1075/15	In combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 15/09/15	15/11/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
botulinum toxin A, 50 Allergan units, 100 Allergan units, 200 Allergan units, powder for solution for injection (Botox®)	692/11	Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine). **Restriction:** where medication overuse has been adequately addressed and, - all appropriate preventative therapies have been tried and are not effective, not tolerated or contraindicated and, - selection of appropriate patients and provision of Botox® is restricted to the NHS Grampian Headache Service.	Routinely available in line with local guidance	21/02/2017
brivaracetam 10mg, 25mg, 75mg, 100mg film-coated tablets, 10mg/mL oral solution, 10mg/mL solution for injection/infusion (Briviact®)	1160/16	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. **SMC restriction:** for use in patients with refractory epilepsy and treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.	Routinely available in line with national guidance, SMC 1160/16 https://www.scottishmedicines.org.uk/media/1369/brivaracetam_briviact_final_june_2016_for_website.pdf Updates decision 19/07/16	20/09/2016
budesonide 3mg gastro-resistant capsules (Budenofalk®)	1043/15	Autoimmune hepatitis. **SMC restriction:** for use in non-cirrhotic patients who are intolerant of conventional oral corticosteroids (prednisolone) with severe corticosteroid-related side effects (actual or anticipated) such as psychosis, poorly controlled diabetes or osteoporosis.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question, Updates decision 19/05/15	21/06/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
budesonide 9mg prolonged release tablets (Cortiment®)	1093/15	In adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient. **SMC restriction:** for use in patients with UC who present with active left-sided disease and/or proctosigmoiditis who are not suitable for oral prednisolone, as an alternative to budesonide rectal formulations or off-label oral budesonide.	Routinely available in line with local guidance, Updates decision 18/10/16	16/02/2021
buprenorphine 2mg, 8mg oral lyophilisate (Espranor®)	1245/17	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction. **SMC restriction:** to patients in whom methadone is not suitable.	Routinely available in line with national guidance, SMC 1245/17 https://www.scottishmedicines.org.uk/media/1386/buprenorphine_oral_lyophilsate_espranor_abb_-_amended_advice_270717.pdf Updates decision 20/06/17	19/03/2019
buprenorphine 5microgram/hour, 10microgram/hour, 15microgram/hour, 20microgram/hour transdermal patch (Butec®)	1213/17	In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. **SMC restriction:** for use in elderly patients (over 65 years).	Routinely available in line with national guidance, SMC 1213/17 https://www.scottishmedicines.org.uk/media/1387/buprenorphine_transdermal_patch_butec_final_dec_2016_for_website.pdf	17/01/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
cabazitaxel 60mg concentrate and solvent for solution for infusion (Jevtana®)	735/11	Cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. **SMC restriction:** for use in patients who have received at least 225mg/m^2 (three cycles) of docetaxel and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.	Routinely available in line with national guidance, SMC 735/11 https://www.scottishmedicines.org.uk/media/1394/cabazitaxel_jevtana_2nd_resub_final_nov_2016_amended_081216_for_website.pdf Updates decision 20/12/16	17/01/2017
cabozantinib 20mg, 40mg, 60mg film-coated tablets (Cabometyx®)	1234/17	For the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.	Routinely available in line with national guidance, SMC 1234/17 https://www.scottishmedicines.org.uk/media/1395/cabozantinib_cabometyx_final_may_2017_for_website.pdf Updates decision 20/06/17	19/09/2017
camellia sinensis (green tea) leaf extract 10% ointment (Catephen®)	1133/16	Cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years. **SMC restriction:** for use in patients not suitable for podophyllotoxin or who have not responded to treatment with podophyllotoxin.	Routinely available in line with local guidance, Updates decision 19/04/16	17/05/2016
canakinumab 150mg powder for solution for injection (Ilaris®)	1210/16	Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris® can be given as monotherapy or in combination with methotrexate.	Not routinely available as not recommended for use in NHS Scotland, SMC 1210/16 https://www.scottishmedicines.org.uk/media/1412/canakinumab_ilaris_non_sub_final_oct_2016_for_website.pdf	15/11/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
canakinumab 150mg powder for solution for injection (Ilaris®)	1268/17	Treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: - tumour necrosis factor receptor associated periodic syndrome - hyperimmunoglobulin D syndrome / mevalonate kinase deficiency - Familial Mediterranean Fever	Not routinely available as not recommended for use in NHS Scotland, SMC 1268/17 https://www.scottishmedicines.org.uk/media/1413/cananki numab_ilaris_non_sub_final_july_2017_for_website.pdf	15/08/2017
cangrelor 50mg powder for concentrate for solution for injection/infusion (Kengrexal®)	1070/15	Co-administered with acetylsalicylic acid for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.	Not recommended for use within NHS Scotland	16/06/2015
capsaicin 179mg cutaneous patch (Qutenza®)	1140/16	Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.	Not recommended for use within NHS Scotland, ADVICE ARCHIVED	15/03/2016
carbetocin 100micrograms/mL solution for injection (Pabal®)	309/06	For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia.	Not routinely available as not recommended for use in NHS Scotland, SMC 309/06 https://www.scottishmedicines.org.uk/media/3094/carbetoc in_pabal_final_dec_2017_for_website.pdf	16/01/2018
carfilzomib 10mg, 30mg, 60mg powder for solution for infusion (Kyprolis®)	1242/17	In combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Routinely available in line with national guidance, SMC 1242/17 https://www.scottishmedicines.org.uk/media/1431/carfilzo mib_kyprolis_final_july_2017_for_website.pdf Updates decision 15/08/17	17/04/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ceftaroline fosamil 600mg powder for concentrate for solution for infusion (Zinforo®)	1306/18	For the treatment of: - complicated skin and soft tissue infections in children from the age of 2 months - community-acquired pneumonia in children from the age of 2 months	Not routinely available as not recommended for use in NHS Scotland, SMC 1306/18 https://www.scottishmedicines.org.uk/media/3095/ceftaroline_fosamil_zinforo_non_sub_final_dec_2017_for_website.pdf	16/01/2018
ceftobiprole 500mg powder for concentrate for solution for infusion (Zevtera®)	943/14	Ceftobiprole is indicated for the treatment of adults with Hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Consideration should be given to official guidance on the appropriate use of antibacterial agents. **SMC restriction:** for use in the treatment of HAP (excluding VAP) when activity is required against suspected methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative pathogens (including Pseudomona aeruginosa, Escherichia coli and Klebsiella pneumoniae) and when combination treatment that includes vancomycin or teicoplanin is inappropriate or has not been tolerated, or when treatment modification is required, i.e. as an alternative to linezolid-based regimens.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 21/07/15	18/08/2015
cefuroxime 50mg powder for solution for injection (Aprokam®)	932/13	Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.	Routinely available in line with national guidance, SMC 932/13 https://www.scottishmedicines.org.uk/media/1444/cefuroxime_aprokam_abbreviated_final_nov_2016_for_website.pdf	20/12/2016
ceritinib 150mg hard capsules (Zykadia®)	1097/15	Treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.	Routinely available in line with regional guidance, Updates decision 15/12/15	18/04/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
certolizumab pegol 200mg solution for injection (Cimzia®)	1155/16	Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.	Not routinely available as not recommended for use in NHS Scotland, SMC 1155/16 https://www.scottishmedicines.org.uk/media/1447/certolizumab_pegol__cimzia__non_sub_final_april_2016_for_website.pdf	17/05/2016
ciclosporin 1mg/mL (0.1%) eye drops emulsion (Ikervis®)	1089/15	Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.	Included on the Grampian Joint Formulary for the indication in question; restricted use	20/10/2015
Cilodex® 3mg/mL / 1mg/mL ear drops (ciprofloxacin / dexamethasone)	1256/17	For treatment of the following infections in adults and children: - acute otitis media in patients with tympanostomy tubes (AOMT) - acute otitis externa **SMC restriction:** treatment of acute otitis media in patients with tympanostomy tubes (AOMT).	This medicine is now withdrawn from use/discontinued Updates decision 18/07/17	21/03/2023
cladribine 10mg tablets (Mavenclad®)	1300/18	Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. **SMC restriction:** - patients with rapidly evolving severe relapsing-remitting MS: patients with two or more relapses in the prior year whether on treatment or not, and at least one T1 gadolinium-enhancing lesion. - patients with sub-optimal therapy relapsing-remitting MS: patients with one or more relapses in the previous year while on disease modifying therapy, and at least one T1 gadolinium-enhancing lesion or nine T2 lesions.	Routinely available in line with national guidance, SMC 1300/18 https://www.scottishmedicines.org.uk/media/3097/cladribine_mavenclad_final_jan_2018_amended_070218_for_website.pdf Updates decision 20/02/18	20/03/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
clostridium botulinum type A toxin-haemagglutinin complex 300, 500 units (Dysport®)	1321/18	Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.	Not routinely available as not recommended for use in NHS Scotland, SMC 1321/18 https://www.scottishmedicines.org.uk/media/3135/clostridium-botulinum-toxin-type-a-dysport-non-sub-final-feb-2018-for-website.pdf	20/03/2018
cobimetinib 20mg film-coated tablets (Cotellic®)	1191/16	In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Not routinely available as not recommended for use in NHS Scotland, SMC 1191/16 https://www.scottishmedicines.org.uk/media/1493/cobimetinib_cotellic_non_sub_final_august_2016_for_website.pdf	20/09/2016
collagenase clostridium histolyticum 0.9mg powder and solvent for solution for injection (Xiapex®)	1059/15	Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.	This medicine is now withdrawn from use/discontinued. Updates decision 19/05/15	17/12/2019
crizotinib 200mg, 250mg hard capsules (Xalkori®)	1152/16	First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).	Routinely available in line with regional guidance, Updates decision 19/07/16	18/04/2017
daclizumab 150mg/mL solution for injection in prefilled syringe/pen (Zinbryta®)	1216/17	In adult patients for the treatment of relapsing forms of multiple sclerosis. **SMC Restriction**: for use: - in patients with rapidly evolving severe (RES) relapsing remitting multiple sclerosis (RRMS) or - in patients with RRMS with an inadequate response to disease modifying therapy	This medicine is now withdrawn from use. The European Medicines Agency (EMA) has recommended the immediate suspension and recall of the multiple sclerosis medicine daclizumab (Zinbryta®). Updates decision 18/04/17	20/03/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
dalbavancin 500mg powder for concentrate for solution for infusion (Xydalba®)	1105/15	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. **SMC restriction:** - for second-line use or when meticillin-resistant Staphylococcus aureus (MRSA) infection is suspected, or on the advice of local microbiologists or specialists in infectious disease, and - the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical condition does not require further inpatient treatment.	Routinely available in line with local guidance, NHS Grampian Staff Guidance for Optimising Use of Alert (Restricted) Antimicrobials in Adults	17/01/2017
daptomycin 350mg, 500mg powder for solution for injection or infusion (Cubicin®)	1309/18	Treatment of paediatric (1 to 17 years of age) patients with *Staphylococcus aureus bacteraemia* associated with complicated skin and soft-tissue infections.	Not routinely available as not recommended for use in NHS Scotland, SMC 1309/18 https://www.scottishmedicines.org.uk/media/3098/daptomicin_cubicin_non_sub_final_jan_2018_for_website.pdf	20/02/2018
daptomycin powder for concentrate for solution for injection or infusion (Cubicin®)	1141/16	Treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.	Not recommended for use within NHS Scotland	15/03/2016
daratumumab 20mg/mL concentrate for solution for infusion (Darzalex®)	1205/17	As monotherapy for use as a fourth line treatment option for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.	Routinely available in line with national guidance, SMC 1205/17 https://www.scottishmedicines.org.uk/media/1521/daratumumab_darzalex_resubmission_final_sept_2017_for_website.pdf Updates decision 17/10/17	19/12/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
darunavir 75mg, 150mg, 400mg, 600mg, 800mg film-coated tablets, 100mg/mL oral suspension (Prezista®)	1069/15	Once daily darunavir co-administered with low dose ritonavir in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in paediatric patients aged 3 to 12 years and ≥15kg who are 1) treatment-naive or 2) treatment-experienced with no darunavir resistance-associated mutations, plasma-HIV-1 RNA <100,000 copies/mL, and CD4+ count >100x10^6 cells/L. **SMC restriction:** to be prescribed under the supervision of specialists in paediatric HIV.	Included on the Grampian Joint Formulary for the indication in question; restricted use	21/07/2015
dasabuvir 250mg film-coated tablets (Exviera®) Viekirax® 12.5mg/75mg/50mg film-coated tablets (ombitasvir/paritaprevir/ritonavir)	1051/15	Ombitasvir/paritaprevir/ritonavir (Viekirax®) for use in combination with dasabuvir (Exviera®) with or without ribavirin for the treatment of genotype 1 chronic hepatitis C (CHC) in adults - Ombitasvir/paritaprevir/ritonavir (Viekirax®) for use in combination with ribavirin for the treatment of genotype 4 CHC in adults.	This medicine is now withdrawn from use/discontinued. Updates decision 16/06/15	16/06/2020
dasatinib 20mg, 50mg, 80mg, 100mg, 140mg film-coated tablets (Sprycel®)	1170/16	For the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/09/2016
dasatinib 20mg, 50mg, 80mg, 100mg, 140mg film-coated tablets (Sprycel®)	370/07	For the treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate.	Routinely available in line with national guidance, SMC 370/07 https://www.scottishmedicines.org.uk/media/1534/dasatinib_sprycel_resub_final_august_2016_amended_060916_for_website.pdf	20/09/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
deferasirox 125mg, 250mg, 500mg dispersible tablets (Exjade®)	347/07	Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias. **SMC restriction:** use in patients with MDS with an International Prognostic Scoring System (IPSS) score of low or intermediate -1 risk.	Routinely available in line with national guidance, SMC 347/07 (Published January 2017) https://www.scottishmedicines.org.uk/media/1540/deferasirox_exjade_resub_final_dec_2016_for_website.pdf Deferasirox film-coated tablets replaced deferasirox dispersible tablets which are discontinued. Updates decision 17/01/17	18/12/2018
deferasirox 90mg, 180mg, 360mg film-coated tablets (Exjade®)	1246/17	**SMC restriction:** deferasirox film-coated tablets are restricted to use as for the SMC advice issued for deferasirox dispersible tablets (No.347/07).	Routinely available in line with national guidance, SMC 347/07 (Published January 2017) https://www.scottishmedicines.org.uk/media/1540/deferasirox_exjade_resub_final_dec_2016_for_website.pdf Deferasirox film-coated tablets replaced deferasirox dispersible tablets which are discontinued. Updates decision 20/06/17	18/12/2018
denosumab 120mg solution for injection (Xgeva®)	1119/15	Adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.	Not recommended for use within NHS Scotland	15/12/2015
dequalinium chloride 10mg vaginal tablets (Fluomizin®)	1194/16	Treatment of bacterial vaginosis in patients for whom the initial treatment is not effective or well tolerated.	Routinely available in line with national guidance, SMC 1194/16 https://www.scottishmedicines.org.uk/media/1551/dequalinium_fluomizin_final_oct_2016_amended_311016_for_website.pdf	15/11/2016
Descovy® 200mg/25mg, 200mg/10mg film coated tablets (emtricitabine/tenofovir alafenamide)	1169/16	In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.	Routinely available in line with national guidance, SMC 1169/16 https://www.scottishmedicines.org.uk/media/1619/emtricitabine_tenofovir_descovy_abb_final_july_2016_for_website.pdf	16/08/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
desmopressin 25microgram, 50microgram oral lyophilisate (Noqdirna®)	1218/17	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. **SMC restriction:** for use in patients aged 65 years and over.	Routinely available in line with national guidance, SMC 1218/17 https://www.scottishmedicines.org.uk/media/1552/desmopressin_noqdirna_resubmission_final_july_2017_for_website.pdf Updates decision 15/08/17	20/11/2018
dexamethasone 40mg tablets (Neofordex®)	1322/18	In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.	Not routinely available as not recommended for use in NHS Scotland, SMC 1322/18 https://www.scottishmedicines.org.uk/media/3136/dexamethasone-neofordex-non-sub-final-feb-2018-for-website.pdf	20/03/2018
dexamethasone 700micrograms intravitreal implant in applicator (Ozurdex®)	1046/15	Treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 19/05/15	16/06/2015
diamorphine hydrochloride 720microgram/actuation, 1600microgram/actuation nasal spray (Ayendi®)	1172/16	Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.	This medicine is now withdrawn from use/discontinued Updates decision 16/08/16	20/10/2020
dolutegravir 10mg, 25mg, 50mg film-coated tablets (Tivicay®)	1253/17	In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age.	Routinely available in line with national guidance, SMC 1253/17 https://www.scottishmedicines.org.uk/media/1579/dolutegravir_tivicay_abbreviated_final_june_2017_for_website.pdf	18/07/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Duaklir® Genuair® 340micrograms/12micrograms inhalation powder (aclidinium/formoterol fumarate dihydrate)	1034/15	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.	Included on the Grampian Joint Formulary for the indication in question, Updates decision 21/04/15	20/10/2015
Duavive® 0.45mg/20mg modified-release tablets (conjugated oestrogens /bazedoxifene acetate)	1220/17	Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.	Not routinely available as not recommended for use in NHS Scotland, SMC 1220/17 https://www.scottishmedicines.org.uk/media/2060/oestrogens_conjugated_duavive_non_sub_final_dec_2016_for_website.pdf	17/01/2017
dulaglutide 0.75mg, 1.5mg solution for injection in pre-filled pen (Trulicity®)	1110/15	In adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. **SMC restriction:** as part of a triple therapy in patients with inadequate glycaemic control on two oral anti-diabetic drugs, as an alternative glucagon-like peptide 1 (GLP-1) agonist option.	Not included on the Grampian Joint Formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine for the indication in question	19/01/2016
Duodopa® 20mg/mL/5mg/mL intestinal gel (co-careldopa (levodopa/carbidopa monohydrate))	316/06	For the treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results. **SMC restriction:** for use in patients not eligible for deep brain stimulation.	Routinely available in line with national guidance, SMC 316/06 https://www.scottishmedicines.org.uk/media/1491/dad_co-careldopa_2nd_resubmission_final_may_2016_for_website.pdf Updates decision 21/06/16	16/08/2016
eculizumab 300mg concentrate for solution for infusion (Soliris®)	767/12	In adults and children for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS).	Not recommended for use within NHS Scotland	16/02/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
eculizumab 300mg/30mL vial concentrate for solution for infusion (Soliris®)	1130/16	In adults and children, for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.	Not routinely available as not recommended for use in NHS Scotland, SMC 1130/16 https://www.scottishmedicines.org.uk/media/1598/eculizumab_soliris_pnh_final_march_2016_for_website.pdf	19/04/2016
edoxaban tosilate 15mg, 30mg, 60mg film-coated tablets (Lixiana®)	1090/15	Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.	Routinely available in line with national guidance, SMC 1090/15 https://www.scottishmedicines.org.uk/media/1599/edoxaban__lixiana__vte_final_october_2015_amended_261015___031115_for_website.pdf Updates decision 17/11/15	21/11/2017
edoxaban tosilate 15mg, 30mg, 60mg film-coated tablets (Lixiana®)	1095/15	For prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).	Routinely available in line with national guidance, SMC 1095/15 https://www.scottishmedicines.org.uk/media/1600/edoxaban__lixiana__nvaf_final_october_2015_amended_031115.pdf Updates decision 17/11/15	21/11/2017
efavirenz 50mg, 100mg, 200mg hard capsules, 600mg film-coated tablets (Sustiva®)	1125/15	Antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.	Included on the Grampian Joint Formulary for the indication in question; restricted use	15/12/2015
eliglustat 84mg hard capsules (Cerdelga®)	1277/17	For the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 poor metabolisers, intermediate metabolisers or extensive metabolisers.	Not routinely available in NHS Grampian. The incidence of Gaucher disease type 1 (GD1) is unpredictable and sporadic. If local need identified National Services Scotland Ultra Orphan Drug Risk Share Arrangement may apply, see https://www.nss.nhs.scot/specialist-healthcare/financial-risk-share/ultra-orphan-drugs-for-rare-diseases/ Updates decision 19/12/17	21/07/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
elosulfase alfa 1mg/mL concentrate for solution for infusion (Vimizim®)	1072/15	Treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.	Not recommended for use within NHS Scotland	15/09/2015
elotuzumab 300mg, 400mg powder for concentrate for solution for infusion (Empliciti®)	1183/16	Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1183/16 https://www.scottishmedicines.org.uk/media/1607/elotuzumab_empliciti_non_sub_final_july_2016_for_website.pdf	16/08/2016
eltrombopag 25mg, 50mg film-coated tablets (Revolade®)	1206/17	Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). **SMC restriction:** use in patients with severe symptomatic ITP or a high risk of bleeding.	Routinely available in line with national guidance, SMC 1206/17 https://www.scottishmedicines.org.uk/media/1608/eltrombopag_revolade_abbreviated_final_dec_2016_for_website.pdf	17/01/2017
eltrombopag olamine 25mg, 50mg film-coated tablets (Revolade®)	1164/16	Treatment in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.	Not routinely available as not recommended for use in NHS Scotland, SMC 1164/16 https://www.scottishmedicines.org.uk/media/1611/eltrombopag_olamine_revolade_non-sub.pdf	21/06/2016
eluxadoline 75mg, 100mg film-coated tablets (Truberzi®)	1292/18	In adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).	This medicine is now withdrawn from use/discontinued Updates decision 16/01/18	21/03/2023
Enstilar® 50micrograms/g / 0.5mg/g cutaneous foam (calcipotriol/betamethasone)	1182/16	Topical treatment of psoriasis vulgaris in adults.	Routinely available in line with local guidance, Updates decision 20/09/16	18/10/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
entecavir 0.5mg, 1mg film-coated tablets, 50micrograms/mL oral solution (Baraclude®)	1049/15	Treatment of chronic hepatitis B virus infection in nucleoside naive paediatric patients from 2 to <18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum alanine aminotransferase levels, or histological evidence of moderate to severe inflammation and/or fibrosis. **SMC restriction:** to be prescribed under the supervision of specialists in paediatric infectious diseases.	Routinely available in line with local guidance, Updates decision 19/05/15	20/06/2017
Entresto® 24mg/26mg, 49mg/51mg, 97mg/103mg film-coated tablets (sacubitril/valsartan)	1132/16	In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.	Included on the Grampian Joint Formulary for the indication in question, Updates decision 15/03/16	17/05/2016
enzalutamide 40mg soft capsules (Xtandi®)	1066/15	Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.	Included on the Grampian Joint Formulary for the indication in question, Updates decision 15/03/16	19/04/2016
Epclusa® 400mg/100mg film-coated tablets (sofosbuvir/velpatasvir)	1195/16	Treatment of chronic hepatitis C virus (HCV) infection in adults. **SMC restriction:** in patients with genotype 3 (GT3) chronic HCV infection.	Routinely available in line with national guidance, National Clinical Guidelines for the treatment of HCV in adults. https://www.hps.scot.nhs.uk/web-resources-container/national-clinical-guidelines-for-the-treatment-of-hcv-in-adults/	15/11/2016
Epclusa® 400mg/100mg film-coated tablets (sofosbuvir/velpatasvir)	1271/17	Treatment of chronic hepatitis C virus (HCV) infection in adults. **SMC restriction:** in patients with: - genotype 2, 5 or 6 chronic HCV infection - decompensated cirrhosis, irrespective of chronic HCV genotype	Routinely available in line with national guidance, SMC 1271/17 https://www.scottishmedicines.org.uk/media/2316/sofosbuvir_velpatasvir_epclusa_final_sept_2017_051017_amended_for_website.pdf	17/10/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
eribulin (mesilate) 0.44mg/mL solution for injection (Halaven®)	1065/15	For the treatment of adult patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. **SMC restriction:** for use in patients with locally-advanced or metastatic breast cancer who have progressive disease after at least two prior chemotherapeutic regimens for advanced disease which includes capecitabine if indicated.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 15/03/16	17/05/2016
etelcalcetide 2.5mg, 5mg, 10mg solution for injection (Parsabiv®)	1262/17	Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1262/17 https://www.scottishmedicines.org.uk/media/1676/etelcalcetide_parsabiv_final_august_2017_amended_030917_for_website.pdf	19/09/2017
everolimus 0.25mg, 0.5mg, 0.75mg tablets (Certican®)	1117/15	For: - prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a cardiac transplant - prophylaxis of organ rejection in patients receiving a hepatic transplant	Not recommended for use within NHS Scotland	17/11/2015
everolimus 0.25mg, 0.5mg, 0.75mg tablets (Certican®)	1288/17	Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.	Not routinely available as not recommended for use in NHS Scotland, SMC 1288/17 https://www.scottishmedicines.org.uk/media/3103/everolimus_certican_non_sub_final_oct_2017_for_website.pdf	21/11/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
everolimus 2.5mg, 5mg, 10mg tablets (Afinitor®)	1215/17	For the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.	Not routinely available as the ADTC is waiting for further advice from local clinical experts, Advice superseded by NICE TA449 Updates decision 21/02/17	18/07/2017
everolimus 2.5mg, 5mg, 10mg tablets (Afinitor®)	872/13	For the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.	Routinely available in line with national guidance, SMC 872/13 https://www.scottishmedicines.org.uk/media/1696/everolimus_afinitor_2nd_resub_final_march_2016_for_website.pdf Updates decision 19/04/16	20/12/2016
evolocumab 140mg solution for injection in pre-filled pen (Repatha® Sureclick) or pre-filled syringe (Repatha® PFS)	1148/16	**SMC restriction:** for specialist use only, when administered at a dose of 140mg every two weeks, in patients at high cardiovascular risk as follows: - patients with heterozygous familial hypercholesterolaemia (HeFH) and LDL-C ≥5.0mmol/L for primary prevention of cardiovascular events or, - patients with HeFH and LDL-C ≥3.5mmol/L for secondary prevention of cardiovascular events or, - patients at high risk due to previous cardiovascular events and LDL-C ≥4.0mmol/L or - patients with recurrent/polyvascular disease and LDL-C ≥3.5mmol/L	Routinely available in line with national guidance, SMC 1148/16 https://www.scottishmedicines.org.uk/media/1701/evolocumab__repatha__resubmission_final_jan_2017_for_website.pdf	21/02/2017
Evotaz® 300mg/150mg film-coated tablets (atazanavir/cobicistat)	1098/15	In combination with other antiretroviral medicinal products for the treatment of HIV-1 infected adults without known mutations associated with resistance to atazanavir.	Not routinely available as there is a local preference for alternative medicines, Updates decision 17/11/15	15/01/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
febuxostat 120mg film-coated tablets (Adenuric®)	1153/16	**SMC restriction**: prevention of hyperuricaemia in adult patients at intermediate risk of TLS in whom allopurinol is either unsuitable or contraindicated, such as: - Those intolerant of allopurinol - Those in whom allopurinol is contraindicated, e.g. patients with renal impairment.	Routinely available in line with national guidance, SMC 1153/16 https://www.scottishmedicines.org.uk/media/1712/dad_febuxostat_adenuric_final_may_2016_for_website.pdf Updates decision 21/06/16	18/12/2018
fentanyl 40micrograms per dose transdermal system (Ionsys®)	1207/16	Management of acute moderate to severe post-operative pain in adult patients.	Not routinely available as not recommended for use in NHS Scotland, SMC 1207/16 https://www.scottishmedicines.org.uk/media/1716/fentanyl_ionsys_non_submission_final_nov_2016_for_website.pdf	20/12/2016
fingolimod 0.5mg hard capsules (Gilenya®)	1038/15	As a single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) for the following adult patient groups: Patients with high disease activity despite treatment with at least one disease modifying therapy.	Routinely available in line with local guidance, Updates decision 21/04/15	21/02/2017
follitropin delta 12micrograms, 36micrograms, 72micrograms solution for injection (Rekovelle®)	1269/17	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.	Not routinely available as not recommended for use in NHS Scotland, SMC 1269/17 https://www.scottishmedicines.org.uk/media/1747/follitropin_rekovelle_non_sub_final_july_2017_for_website.pdf	15/08/2017
fosfomycin trometamol granules for oral solution (equivalent to 3g fosfomycin) (Monuril®)	1163/16	Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females.	Routinely available in line with local guidance	20/09/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
fulvestrant 250mg solution for injection (Faslodex®)	114/04	For the treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen.	Routinely available in line with national guidance, SMC 114/04 https://www.scottishmedicines.org.uk/files/advice/fulvestrant_Faslodex_Resub_FINAL_Jan_2016_for_website.pdf Updates decision 16/02/16	21/03/2017
fulvestrant 250mg solution for injection (Faslodex®)	1294/17	Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1294/17 https://www.scottishmedicines.org.uk/media/3105/fulvestrant_faslodex_non_sub_final_nov_2017_for_website.pdf	19/12/2017
gefitinib 250mg film-coated tablets (Iressa®)	615/10	The treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal growth factor receptor tyrosine kinase (EGFR-TK). **SMC restriction:** in patients with previously untreated locally advanced or metastatic NSCLC with activating EGFR-TK mutations i.e. as a first-line therapy.	Not routinely available as there is a local preference for alternative medicines, Updates decision 15/12/15	18/08/2020
Genvoya® 150mg/150mg/200mg/10mg film-coated tablets (elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide)	1323/18	Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight at least 25kg for whom alternative regimens are unsuitable due to toxicities. **Restriction:** to be prescribed under the supervision of specialists in paediatric HIV.	Not routinely available as not recommended for use in NHS Scotland, ADVICE ARCHIVED, replaced by FG advice published 31/05/2021 (FG meeting 18/05/2021).	20/03/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Genvoya® 150mg/150mg/200mg/10mg film-coated tablets (elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide)	1142/16	For the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.	Routinely available in line with national guidance, SMC 1142/16 https://www.scottishmedicines.org.uk/media/1613/elvitegravir__genvoya__final_april_2016_for_website.pdf	17/05/2016
glatiramer acetate 40mg/mL solution for injection prefilled syringes (Copaxone®)	1108/15	Treatment of relapsing forms of multiple sclerosis (MS).	Included on the Grampian Joint Formulary for the indication in question; restricted use	15/12/2015
glycopyrronium 320micrograms/mL (glycopyrronium bromide 400micrograms/mL) oral solution (Sialanar®)	1254/17	Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.	Routinely available in line with local guidance, Updates decision 18/07/17	15/09/2020
golimumab 50mg/0.5mL solution for injection in pre-filled pen or syringe, 100mg/mL solution for injection in pre-filled pen (Simponi®)	1124/16	For the treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 16/02/16	15/03/2016
guanfacine 1mg, 2mg, 3mg, 4mg prolonged-release tablets (Intuniv®)	1123/16	Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.	Routinely available in line with local guidance, NHS Grampian prescribing guidance for ADHD in children and adolescents Updates decision 16/02/16	20/12/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Harvoni® 90mg/400mg film-coated tablets (ledipasvir/sofosbuvir)	1084/15	Treatment of genotype 3 chronic hepatitis C (CHC) in adults. **SMC restriction:** patients who are ineligible for or unable to tolerate interferon.	Included on the Grampian Joint Formulary for the indication in question; restricted use	15/09/2015
human alpha1-proteinase inhibitor 1,000mg powder and solvent for solution for infusion (Respreeza®)	1157/16	For maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor (A1-PI) deficiency.	Not routinely available as not recommended for use in NHS Scotland, SMC 1157/16 https://www.scottishmedicines.org.uk/media/1794/human_alpha_1_proteinase_inhibitor_respreeza_final_july_2016_updated_180716_for_website.pdf	16/08/2016
hydrocortisone 5mg, 20mg modified-release tablets (Plenadren®)	848/12	Treatment of adrenal insufficiency in adults.	Not routinely available as not recommended for use in NHS Scotland, SMC 848/12 https://www.scottishmedicines.org.uk/media/1795/hydrocortisone_plenadren_final_nov_2016_for_website.pdf	20/12/2016
ibrutinib 140mg hard capsules (Imbruvica®)	1150/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).	Routinely available in line with national guidance, SMC 1150/16 https://www.scottishmedicines.org.uk/media/1806/ibrutinib_imbruvica_mcl_final_july_2016_for_website.pdf Updates decision 16/08/16	15/11/2016
ibrutinib 140mg hard capsules (Imbruvica®)	1151/16	Treatment of adult patients with chronic lymphocytic leukaemia (CLL). **SMC restriction:** (first-line for) patients with 17p deletion or TP53 mutation who are unsuitable for chemo-immunotherapy.	Routinely available in line with national guidance, SMC 1151/16 published 08/08/2016 https://www.scottishmedicines.org.uk/media/2674/ibrutinib__imbruvica__cll_final_july_2016_amended_300716_for_website.pdf Also see SMC resubmission published 10/04/2017 https://www.scottishmedicines.org.uk/media/1804/ibrutinib_imbruvica_resub_final_march_2017_for_website.pdf Updates decision 16/08/16	15/11/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
ibrutinib 140mg hard capsules (Imbruvica®)	1151/16	The treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. **SMC restriction**: patients with relapsed/refractory CLL and for whom fludarabine-based regimens are inappropriate.	Routinely available in line with national guidance, SMC 1151/16 https://www.scottishmedicines.org.uk/media/1804/ibrutinib_imbruvica_resub_final_march_2017_for_website.pdf Updates decision 18/04/17	21/11/2017
ibrutinib 140mg hard capsules (Imbruvica®)	1258/17	In combination with bendamustine and rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1258/17 https://www.scottishmedicines.org.uk/media/1805/ibrutinib_imbruvica_non_sub_final_may_2017_for_website.pdf	20/06/2017
ibrutinib 140mg hard capsules (Imbruvica®)	1289/17	As a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (who do not have 17p deletion or TP53 mutation).	Not routinely available as not recommended for use in NHS Scotland, SMC 1289/17 https://www.scottishmedicines.org.uk/media/3107/ibrutinib_imbruvica_non_sub_final_oct_2017_for_website.pdf	21/11/2017
idarucizumab 2.5g/50mL solution for injection/infusion (Praxbind®)	1178/16	Idarucizumab is a specific reversal agent for dabigatran and is indicated in adult patients treated with dabigatran etexilate when rapid reversal of its anticoagulant effects is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.	Routinely available in line with local guidance	20/09/2016
idebenone 150mg film-coated tablets (Raxone®)	1226/17	Treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON). **SMC restriction:** to patients with LHON who are not yet blind i.e. they do not meet the UK criteria to be registered as severely sight impaired.	Not routinely available as local implementation plans are being developed, Updates decision 20/06/17	17/10/2017
idelalisib 100mg, 150mg film-coated tablets (Zydelig®)	1039/15	Monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment.	Included on the Grampian Joint Formulary for the indication in question; restricted use	19/05/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
insulin aspart 100units/mL solution for injection in vial (Fiasp®), solution for injection in cartridge (Fiasp® Penfill®), solution for injection in pre-filled pen (Fiasp® FlexTouch®)	1227/17	Treatment of diabetes mellitus in adults.	Routinely available in line with local guidance, Updates decision 18/04/17	19/10/2017
insulin degludec 100units/mL solution for injection in pre-filled pen or cartridge, 200units/mL solution for injection in pre-filled pen (Tresiba®)	856/13	Treatment of diabetes mellitus in adults.	Routinely available in line with national guidance, SMC 856/13 https://www.scottishmedicines.org.uk/media/1850/insulin_degludec_tresiba_2ndresub_final_july_2016_updated_300716_for_website.pdf Updates decision 16/08/16	20/06/2017
insulin degludec 100units/mL solution for injection in pre-filled pen or cartridge, 200units/mL solution for injection in pre-filled pen (Tresiba®)	1060/15	Treatment of diabetes mellitus in adults, adolescents and children from the age of one year.	Not recommended for use within NHS Scotland, ADVICE ARCHIVED	19/05/2015
insulin detemir 100units/mL solution for injection in cartridge, pre-filled pen (Levemir®)	1126/16	For treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. **SMC restriction:** in patients unable to achieve good glycaemic control with established insulins.	Included on the Grampian Joint Formulary for the indication in question; restricted use	15/03/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
insulin glargine 300units/mL solution for injection in a pre-filled pen (Toujeo®)	1078/15	Treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above. **SMC restriction:** its use should be targeted on patients with Type I diabetes who are at risk of or experience unacceptable frequency and/or severity of nocturnal hypoglycaemia on attempting to achieve better hypoglycaemic control during treatment with established insulins. It is also acceptable as a once daily insulin therapy for patients who require carer administration of their insulin. In patients with type 2 diabetes it should be restricted to those who suffer from recurrent episodes of hypoglycemia or require assistance with their insulin injections.	Not included on the Grampian Joint Formulary because risk minimisation strategies are required to allow safe introduction.	15/09/2015
Invicorp® 25micrograms/2mg solution for injection (aviptadil/phentolamine)	1284/17	For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology. **SMC restriction:** for use in those who have failed on oral therapies (oral phosphodiesterase type-5 inhibitors) and other non-injectable formulations of erectile dysfunction medications.	Routinely available in line with national guidance, SMC 1284/17 https://www.scottishmedicines.org.uk/media/3091/aviptadil_phentolamine_mesilate_invicorp_final_nov_2017_for_website.pdf Updates decision 19/12/17	19/06/2018
irinotecan hydrochloride trihydrate (as irinotecan sucrosofate salt), 5mg/mL concentrate for solution for infusion (Onivyde®)	1217/17	Treatment of metastatic adenocarcinoma of the pancreas, in combination with fluorouracil (5-FU) and leucovorin (folinic acid), in adult patients who have progressed following gemcitabine based therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1217/17 https://www.scottishmedicines.org.uk/media/1945/liposomal_irinotecan_onivyde_final_feb_2017_for_website.pdf	21/03/2017
iron (III) isomaltoside 1000 (contains 50mg iron per mL) solution for injection (Diafer®)	1177/16	For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	21/02/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
isavuconazole 200mg powder for concentrate for solution for infusion, 100mg hard capsules (Cresemba®)	1129/16	In adults for the treatment of: - invasive aspergillosis - mucormycosis in patients for whom amphotericin B is inappropriate	Routinely available in line with local guidance, Updates decision 19/04/16	17/05/2016
ivacaftor 150mg film-coated tablets (Kalydeco®)	1193/16	For the treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CF transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHS Scotland, SMC 1193/16 https://www.scottishmedicines.org.uk/media/1880/ivacaftor__kalydeco__final_nov_2016_for_website.pdf	20/12/2016
ivacaftor 50mg, 75mg granules in sachet (Kalydeco®)	1134/16	For the treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25kg who have one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.	Not routinely available as not recommended for use in NHS Scotland, SMC 1134/16 https://www.scottishmedicines.org.uk/media/1879/ivacaftor_granules__kalydeco__final_april_2016_for_website.pdf	17/05/2016
ivermectin 10mg/g cream (Soolantra®)	1104/15	Topical treatment of inflammatory lesions of rosacea (papulopustular) in adult patients. **SMC restriction:** the treatment of moderate to severe inflammatory lesions of rosacea where a topical treatment is considered appropriate.	Included on the Grampian Joint Formulary for the indication in question, Updates decision 15/12/15	17/05/2016
ixekizumab 80mg solution for injection (Taltz®)	1223/17	Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **SMC restriction:** patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Routinely available in line with national guidance, SMC 1223/17 https://www.scottishmedicines.org.uk/media/1883/ixekizumab_taltz_final_march_2017_amended_050417_for_website.pdf Updates decision 18/04/17	18/07/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Jentadueto® 2.5mg/850mg, 2.5mg/1000mg film-coated tablets (linagliptin/metformin)	1057/15	For the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control. **SMC restriction:** to use in patients for whom a combination of linagliptin and metformin is an appropriate choice of therapy and the fixed doses are considered appropriate.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question	16/06/2015
Kaletra® 80mg/20mg oral solution (lopinavir/ritonavir)	1302/18	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to ≤2 years.	Routinely available in line with national guidance, SMC 1302/18 https://www.scottishmedicines.org.uk/media/3110/lopinavir-ritonavir_kaletra_abb_final_jan_2018_for_website.pdf	20/02/2018
ketoconazole 200mg tablets (Ketoconazole HRA®)	1100/15	Treatment of endogenous Cushing's syndrome in adults and adolescents above the age of 12 years.	Not recommended for use within NHS Scotland	15/09/2015
lacosamide 50mg, 100mg, 150mg, 200mg film-coated tablets, 10mg/mL solution for infusion, 10mg/mL syrup (Vimpat®)	1231/17	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1231/17 https://www.scottishmedicines.org.uk/media/1888/lacosamide_vimpat_non_sub_final_feb_2017_for_website.pdf	21/03/2017
lacosamide 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup, 10mg/mL solution for intravenous infusion (Vimpat®)	1301/18	As adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years to <16 years of age with epilepsy. **SMC restriction:** patients with refractory epilepsy. Treatment should be initiated by physicians who have appropriate experience in the treatment of epilepsy.	Routinely available in line with national guidance, SMC 1301/18 https://www.scottishmedicines.org.uk/media/3108/lacosamide_vimpat_abbreviated_final_jan_2018_for_website.pdf	20/02/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
lacosamide 50mg, 100mg, 150mg, 200mg tablets, 10mg/mL syrup, 10mg/mL solution for intravenous infusion (Vimpat®)	1324/18	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1324/18 https://www.scottishmedicines.org.uk/media/3138/lacosamide-vimpat-non-sub-final-feb-2018-for-website.pdf	20/03/2018
lenalidomide 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg hard capsules (Revlimid®)	1211/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma.	Not routinely available as not recommended for use in NHS Scotland, SMC 1211/16 https://www.scottishmedicines.org.uk/media/1908/lenalidomide_revlimid_non_sub_final_oct_2016_for_website.pdf	15/11/2016
lenalidomide, 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg capsules (Revlimid®)	1096/15	Treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. **SMC restriction:** for use in patients unsuitable for thalidomide-containing regimens	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 15/12/15	21/06/2016
lenvatinib 4mg, 10mg hard capsules (Lenvima®)	1179/16	Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).	Routinely available in line with national guidance, SMC 1179/16 https://www.scottishmedicines.org.uk/media/1913/lenvatinib_lenvima_final_sept_2016_amended_300916_for_website.pdf Updates decision 18/10/16	21/03/2017
levofloxacin 240mg nebuliser solution (Quinsair®)	1162/16	The management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. **SMC restriction:** for use as a third line treatment option after colistimethate sodium (first line) and tobramycin (second line).	Routinely available in line with national guidance, SMC 1162/16 https://www.scottishmedicines.org.uk/media/1930/levofloxacin_quinsair_final_june_2016_updated_300716_for_website.pdf Updates decision 16/08/16	21/08/2018
levonorgestrel 13.5mg intrauterine delivery system (Jaydess®)	1036/15	Contraception for up to 3 years.	Included on the Grampian Joint Formulary for the indication in question, Updates decision 21/04/15	19/05/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
levonorgestrel 19.5mg intrauterine delivery system (Kyleena®)	1299/18	Contraception for up to 5 years.	Routinely available in line with national guidance, SMC 1299/18 https://www.scottishmedicines.org.uk/media/3109/levonorgestrel_kyleena_final_jan_2018_for_website.pdf Updates decision 20/02/18	15/05/2018
levonorgestrel 20micrograms/24 hours intrauterine delivery system (Levosert®)	1058/15	- Contraception. - Heavy menstrual bleeding.	Routinely available in line with local guidance, Updates decision 16/06/15	19/03/2019
linagliptin 5mg tablets (Trajenta®)	850/13	The treatment of type 2 diabetes mellitus to improve glycaemic control in adults in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question	19/05/2015
liraglutide 6mg/mL pre-filled pen for injection (3mL) (Victoza®)	1044/15	For the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with basal insulin when this, together with diet and exercise, does not provide adequate glycaemic control.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question, Updates decision 19/05/15	20/10/2015
liraglutide 6mg/mL solution for injection in pre-filled pen (Victoza®)	1192/16	As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.	Not routinely available as not recommended for use in NHS Scotland, SMC 1192/16 https://www.scottishmedicines.org.uk/media/1948/liraglutide_victoza_non_sub_final_august_2016_for_website.pdf	20/09/2016
lisdexamfetamine dimesylate 30mg, 50mg, 70mg hard capsules (Elvanse Adult®)	1079/15	As part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Based on clinical judgment, patients should have ADHD of at least moderate severity.	Not included on the Grampian Joint Formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine for the indication in question	15/09/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Lonsurf® 15mg/6.14mg, 20mg/8.19mg film-coated tablets (trifluridine/tipiracil)	1221/17	The treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.	Routinely available in line with regional guidance	21/02/2017
magnesium aspartate dihydrate equivalent to 243mg (10mmol) of magnesium powder for oral solution (Magnaspartate®)	1042/15	For the treatment and prevention of magnesium deficiency, as diagnosed by a doctor.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 16/06/15	18/08/2015
magnesium glycerophosphate 4mmoL chewable tablets (Neomag®)	1267/17	As an oral magnesium supplement for the treatment of patients with chronic magnesium loss or hypomagnesaemia as diagnosed by a doctor.	Routinely available in line with national guidance, SMC 1267/17 https://www.scottishmedicines.org.uk/media/1966/magnesium_glycerophosphate_neomag_abb_final_august_2017_for_website.pdf	19/09/2017
maraviroc 20mg/mL oral solution, 25mg, 75mg, 150mg, 300mg film-coated tablets (Celsentri®)	1282/17	In combination with other antiretroviral medicinal products for treatment-experienced adolescents and children aged 2 years to <18 years and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable.	Not routinely available as not recommended for use in NHS Scotland, SMC 1282/17 https://www.scottishmedicines.org.uk/media/1968/maraviroc_celsentri_non_sub_final_sept_2017_for_website.pdf	17/10/2017
Maviret® 100mg/40mg film-coated tablets (glecaprevir/pibrentasvir)	1278/17	Treatment of chronic hepatitis C virus (HCV) infection in adults.	Routinely available in line with national guidance, SMC 1278/17 https://www.scottishmedicines.org.uk/media/3106/glecaprevir_pibrentasvir_maviret_final_oct_2017_amended_301017_for_website.pdf	21/11/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
mepolizumab 100mg powder for solution for injection (Nucala®)	1149/16	As an add-on treatment for severe refractory eosinophilic asthma in adult patients. **SMC restriction:** patients who have eosinophils of at least 150 cells per microlitre (0.15 x 10^9/L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.	Routinely available in line with national guidance, SMC 1149/16 https://www.scottishmedicines.org.uk/media/1976/dad_mepolizumab_oesinophilic_asthma_final_may_2016_amended_080616_100616_for_website.pdf, Updates decision 21/06/16	20/09/2016
metformin hydrochloride 500mg, 750mg, 1000mg prolonged release tablets (Glucophage SR®)	1308/18	Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: - at high risk for developing overt type 2 diabetes mellitus and - still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months	Not routinely available as not recommended for use in NHS Scotland, SMC 1308/18 https://www.scottishmedicines.org.uk/media/3112/metformin_hydrochloride_glucophage_non_sub_final_dec_2017_for_website.pdf	16/01/2018
micronised progesterone 200mg vaginal capsules (Utrogestan Vaginal®)	935/13	In women for supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/06/2017
midazolam (as maleate) 10mg/1mL oromucosal solution prefilled syringe (Epistatus®)	1279/17	Treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years.	Routinely available in line with local guidance. Updates decision 21/11/17	20/02/2018
midodrine hydrochloride 2.5mg, 5mg tablets (Bramox®)	1094/15	In adults for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate.	Included on the Grampian Joint Formulary for the indication in question; restricted use	20/10/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
migalastat 123mg hard capsules (Galafold®)	1196/16	Long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation. **SMC restriction:** in males with classic mutations (leucocyte enzyme activity <1%) treatment should commence at diagnosis; in females and those males with later onset mutations with higher levels of leucocyte enzyme activity, treatment should commence when patients experience uncontrolled pain, evidence of renal, cardiac or neurovascular disease, or gastrointestinal symptoms that significantly reduce quality of life.	Not routinely available in NHS Grampian. The incidence of Fabry disease is unpredictable and sporadic. If local need identified National Services Scotland Ultra Orphan Drug Risk Share Arrangement apply, see https://www.nss.nhs.scot/specialist-healthcare/financial-risk-share/inherited-metabolic-disorders/. Updates decision 15/11/16	21/07/2020
naloxegol 12.5mg, 25mg film-coated tablets (Moventig®)	1106/15	The treatment of opioid-induced constipation in adult patients who have had an inadequate response to laxative(s).	Routinely available in line with local guidance, ADVICE ARCHIVED, replaced by FG advice published 04/07/2022 (FG meeting 21/06/2022). Updates decision 15/12/15	19/01/2021
naproxen 250mg effervescent tablets (Stirlescent®)	1154/16	For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults. **SMC restriction:** use in patients unable to swallow naproxen tablets.	Not routinely available as there is a local preference for alternative medicines	21/06/2016
necitumumab 800mg concentrate for solution for infusion (Portrazza®)	1184/16	In combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.	This medicine is now withdrawn from use/discontinued Updates decision 16/08/16	19/01/2021
nepafenac 3mg/mL eye drops suspension (Nevanac®)	1228/17	Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	20/06/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nilotinib 150mg, 200mg hard capsules (Tasigna®)	1325/18	For the treatment of: - paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase - paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib	Not routinely available as not recommended for use in NHS Scotland, SMC 1325/18 https://www.scottishmedicines.org.uk/media/3139/nilotinib-tasigna-non-sub-final-feb-2018-for-website.pdf	20/03/2018
nintedanib 100mg, 150mg capsules (Ofev®)	1076/15	In adults for the treatment of idiopathic pulmonary fibrosis (IPF). **SMC restriction:** For use in patients with a predicted forced vital capacity (FVC) less than or equal to 80%.	Included on the Grampian Joint Formulary for the indication in question; restricted use	20/10/2015
nintedanib 100mg, 150mg soft capsules (Vargatef®)	1027/15	In combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first-line chemotherapy.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 21/04/15	15/09/2015
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1120/16	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. **SMC restriction:** patients previously untreated with ipilimumab.	Routinely available in line with regional guidance, Updates decision 16/08/16	18/10/2016
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1144/16	Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Routinely available in line with regional guidance, Updates decision 19/07/16	18/10/2016
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1180/16	Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults. **SMC restriction:** treatment with nivolumab is subject to a two-year clinical stopping rule.	Routinely available in line with regional guidance	18/10/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1187/16	In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults. **SMC restriction:** for the first-line treatment of advanced melanoma.	Routinely available in line with regional guidance, Updates decision 15/11/16	20/02/2018
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1188/16	As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.	Routinely available in line with national guidance, SMC 1188/16 https://www.scottishmedicines.org.uk/media/2049/nivolumab_opdivo_resubmission_final_may_2017_for_website.pdf Updates decision 20/06/17	19/09/2017
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1240/17	The treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.	Routinely available in line with national guidance, SMC 1240/17 https://www.scottishmedicines.org.uk/media/2051/nivolumab_opdivo_chl_final_june_2017_for_website.pdf Updates decision 18/07/17	21/05/2019
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1261/17	As monotherapy, for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy. **SMC restriction**: treatment with nivolumab is subject to a two year clinical stopping rule.	Routinely available in line with national guidance, SMC 1261/17 https://www.scottishmedicines.org.uk/media/2050/nivolumab_opdivo_final_august_2017_for_website.pdf Updates decision 19/09/17	17/10/2017
nivolumab 10mg/mL concentrate for solution for infusion (Opdivo®)	1285/18	As monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1285/18 https://www.scottishmedicines.org.uk/media/3114/nivolumab_opvido_final_dec_2017_for_website.pdf	16/01/2018
obeticholic acid 5mg, 10mg film-coated tablets (Ocaliva®)	1232/17	For the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid.	Routinely available in line with national guidance, SMC 1232/17 https://www.scottishmedicines.org.uk/media/2055/obeticholic_acid_ocaliva_final_may_2017_amended_170517_for_website.pdf Updates decision 20/06/17	19/12/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
obinutuzumab 1,000mg concentrate for solution for infusion (Gazyvaro®)	1219/17	Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.	Routinely available in line with national guidance, SMC 1219/17 https://www.scottishmedicines.org.uk/media/2057/obinutuzumab_gazyvaro_final_feb_2017_updated_130217_for_website.pdf Updates decision 21/03/17	18/12/2018
Odefsey® 200mg/25mg/245mg (emtricitabine/rilpivirine/tenofovir alafenamide)	1189/16	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.	Routinely available in line with national guidance, SMC 1189/16 https://www.scottishmedicines.org.uk/media/2235/rilpivirine_emtricitabine_odefsey_abbreviated_final_sept_2016_for_website.pdf	18/10/2016
ofatumumab 100mg, 1,000mg concentrate for solution for infusion (Arzerra®)	1037/15	Ofatumumab in combination with chlorambucil or bendamustine is indicated for the treatment of patients with chronic lymphocytic leukaemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy. **SMC restriction:** for use in patients who would not be considered for bendamustine therapy and who would receive chlorambucil-based therapy.	This medicine is now withdrawn from use in the European Union, Updates decision 19/05/15	21/05/2019
ofatumumab 100mg, 1000mg concentrate for solution for infusion (Arzerra®)	1237/17	Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclosphosphamide.	This medicine is now withdrawn from use in the European Union. Jan 18: Novartis announced withdrawal of ofatumumab for CLL from markets outside the US due to low numbers of patients using the treatment. The company will set up compassionate use programmes so that current patients can continue treatment. Development will continue for refractory NHL and multiple sclerosis indications. Updates decision 18/04/17	21/05/2019

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
olaparib 50mg hard capsules (Lynparza®)	1047/15	Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.	This medicine is now withdrawn from use/discontinued, Olaparib capsules are discontinued. ADVICE ARCHIVED, replaced by SMC 2367 - SMC abbreviated subbmission (for olaparib tablets). See FG advice published 30/05/2022 (FG meeting 17/05/2022). Updates decision 15/11/16	17/05/2022
olaratumab 10mg/mL concentrate for solution for infusion (Lartruvo®)	1273/17	In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin. **SMC restriction:** for use in combination with doxorubicin as first-line treatment for advanced soft-tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.	The EMA has recommended that the marketing authorisation of the medicine be revoked. 26/04/2019 EMA has completed its assessment of the results of the ANNOUNCE study and concluded that olaratumab (Lartruvo®) with doxorubicin does not prolong the lives of patients with soft tissue cancer more than doxorubicin alone. The Agency is therefore recommending that the marketing authorisation of the medicine be revoked. Updates decision 21/11/17	21/05/2019
Orkambi® 200mg/125mg film-coated tablets (lumacaftor/ivacaftor)	1136/16	For the treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHS Scotland, SMC 1136/16 https://www.scottishmedicines.org.uk/media/1961/lumacaftor-ivacaftor__orkambi__final_april_2016_for_website.pdf	17/05/2016
oseltamivir 30mg, 45mg, 75mg capsules, 6mg/mL powder for oral suspension (Tamiflu®)	1127/16	Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.	Included on the Grampian Joint Formulary for the indication in question; restricted use	15/03/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
osimertinib 40mg, 80mg film-coated tablets (Tagrisso®)	1214/17	The treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC). **SMC restriction:** in patients who have received previous treatment with an EGFR tyrosine kinase inhibitor.	Routinely available in line with regional guidance	21/02/2017
paclitaxel formulated as albumin bound nanoparticles 5mg/mL powder for suspension for infusion (Abraxane®)	1071/15	In combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Not recommended for use within NHS Scotland	16/06/2015
palbociclib 75mg, 100mg, 125mg hard capsules (Ibrance®)	1276/17	Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or peri-menopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. **SMC restriction:** in combination with an aromatase inhibitor for first-line treatment of HR-positive HER2-negative locally advanced or metastatic breast cancer.	Routinely available in line with national guidance, SMC 1276/17 https://www.scottishmedicines.org.uk/media/3260/palbociclib-ibrance-final-nov-2017-for-website.pdf Updates decision 19/12/17	16/01/2018
paliperidone palmitate 175mg, 263mg, 350mg, 525mg prolonged release suspension for injection (Trevicta®)	1181/16	Paliperidone palmitate (Trevicta®), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.	Routinely available in line with national guidance, SMC 1181/16 https://www.scottishmedicines.org.uk/media/2103/paliperidone_palmitate_trevicta_abb_final_august_2016_for_website.pdf	20/09/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
palonosetron 250micrograms solution for injection (Aloxi®)	1073/15	Prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, in paediatric patients 1 month of age and older.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question, Updates decision 18/08/15	21/06/2016
panitumumab 20mg/mL concentrate for solution for infusion (Vectibix®)	1082/15	Treatment of adult patients with wild-type RAS metastatic colorectal cancer first-line in combination with FOLFIRI.	Not recommended for use within NHS Scotland, Advice superseded by NICE TA439	21/07/2015
panobinostat, 10mg, 15mg, 20mg hard capsules (Farydak®)	1122/16	In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 16/02/16	16/08/2016
pasireotide (as pamoate) 10mg, 20mg, 30mg, 40mg powder and solvent for suspension for injection (Signifor®)	1311/18	Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.	Not routinely available as not recommended for use in NHS Scotland, SMC 1311/18 https://www.scottishmedicines.org.uk/media/3118/pasireotide_signifor_non_sub_final_jan_2018_for_website.pdf	20/02/2018
pasireotide (as pamoate) 20mg, 40mg 60mg powder and solvent for suspension for injection (Signifor®)	1048/15	Treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 15/09/15	20/10/2015
pegaspargase 750U/mL solution for injection/infusion (Oncaspar®)	1197/16	As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.	Routinely available in line with national guidance, SMC 1197/16 https://www.scottishmedicines.org.uk/media/2124/pegaspargase_oncaspar_abb_final_oct_2016_for_website.pdf	15/11/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
peginterferon alfa-2a 135micrograms, 180micrograms solution for injection in pre-filled pen, 90micrograms, 135micrograms, 180micrograms solution for injection in pre-filled syringe (Pegasys®)	1312/18	Treatment of hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.	Not routinely available as not recommended for use in NHS Scotland, SMC 1312/18 https://www.scottishmedicines.org.uk/media/3119/peginterferon_alfa-2a_pegasys_non_sub_final_jan_2018_for_website.pdf	20/02/2018
pegvisomant 10mg, 15mg, 20mg, 25mg, 30mg powder and solvent for solution for injection (Somavert®)	158/05	Treatment of adult patients with acromegaly who have had an inadequate response to surgery and / or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 [insulin-like growth factor 1] concentrations or was not tolerated.	Routinely available in line with national guidance, SMC 158/05 https://www.scottishmedicines.org.uk/media/3120/pegvisomant__somavert__2nd_resub_final_oct_2017_for_website_amended061217.pdf Updates decision 21/11/17	19/12/2017
pembrolizumab 25mg/mL concentrate for solution for infusion, 50mg powder for concentrate for solution for infusion (Keytruda®)	1239/17	As monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tumour mutations. **SMC restriction:** treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 1239/17 https://www.scottishmedicines.org.uk/media/2142/pembrolizumab_keytruda_final_june_2017_for_website.pdf Updates decision 18/07/17	21/11/2017
pembrolizumab 25mg/mL concentrate for solution for infusion, 50mg powder for concentrate for solution for infusion (Keytruda®)	1291/18	As monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy. **SMC restriction:** treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 1291/18 https://www.scottishmedicines.org.uk/media/3121/pembrolizumab_keytruda_final_jan_2018_for_website.pdf Updates decision 20/02/18	20/03/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
pembrolizumab 25mg/mL concentrate for solution for infusion, 50mg powder for concentrate for solution for infusion (Keytruda®)	1296/18	As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin. **SMC restriction**: treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with national guidance, SMC 1296/18 https://www.scottishmedicines.org.uk/media/3140/pembrolizumab-keytruda-chl-final-feb-2018-for-website.pdf Updates decision 20/03/18	18/12/2018
pembrolizumab 50mg powder for concentrate for solution for infusion (Keytruda®)	1086/15	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously untreated with ipilimumab.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 17/11/15	21/06/2016
pembrolizumab 50mg powder for concentrate for solution for infusion (Keytruda®)	1087/15	As monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.	Not routinely available as not recommended for use in NHS Scotland, SMC 1087/15 https://www.scottishmedicines.org.uk/media/2140/pembrolizumab_keytruda_resub_final_nov_2016_for_website.pdf	20/12/2016
pembrolizumab 50mg powder for concentrate for solution for infusion (Keytruda®)	1204/17	The treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one prior chemotherapy regimen. **SMC restriction:** treatment with pembrolizumab is subject to a two-year clinical stopping rule.	Routinely available in line with regional guidance	17/01/2017
perampanel 2mg, 4mg, 6mg, 8mg, 10mg, 12mg film-coated tablets (Fycompa®)	1200/16	Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1200/16 https://www.scottishmedicines.org.uk/media/2154/perampanel_fycompa_non_sub_final_sept_2016_for_website.pdf	18/10/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
pitolisant 4.5mg, 18mg film-coated tablets (Wakix®)	1229/17	Treatment of narcolepsy with or without cataplexy in adults.	Not routinely available as not recommended for use in NHS Scotland, SMC 1229/17 https://www.scottishmedicines.org.uk/media/2169/pitolisant_wakix_non_sub_final_jan_2017_for_website.pdf	21/02/2017
pixantrone 29mg power for concentrate for solution for infusion (Pixuvri®)	1138/16	As monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas.	Not recommended for use within NHS Scotland	16/02/2016
ponatinib 15mg, 45mg film-coated tablets (Iclusig®)	1032/15	Adult patients with: chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 21/04/15	19/05/2015
posaconazole 300mg concentrate for solution for infusion (Noxafil®)	1067/15	See SMC advice for indications.	Routinely available in line with local guidance	21/07/2015
progesterone 100mg vaginal tablets (Lutigest®)	1185/16	Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	18/10/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Qtern® 5mg/10mg film-coated tablets (saxagliptin/dapagliflozin)	1255/17	In adults aged 18 years and older with type 2 diabetes mellitus: - to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Qtern® do not provide adequate glycaemic control - when already being treated with the free combination of dapagliflozin and saxagliptin **SMC restriction:** for use in combination with metformin when the use of a sulphonylurea is inappropriate.	Not routinely available as there is a local preference for alternative medicines	18/07/2017
radium-223 dichloride 1000kBq/mL solution for injection (Xofigo®)	1077/15	For the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 20/10/15	15/12/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
raltegravir 100mg granules for oral suspension (Isentress®)	1102/15	In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults, adolescents, children, toddlers and infants from the age of 4 weeks. **SMC restriction:** patients who are intolerant or resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) or when these options are compromised due to drug-drug interactions; raltegravir granules should be prescribed under the supervision of specialists in paediatric HIV. The granules for oral suspension are licensed for use in patients weighing 3kg to 20kg and provide an alternative formulation for infants where chewable tablets are not suitable. Because the formulations are not bioequivalent, neither the granules for oral suspension nor the chewable tablets should be substituted for the 400mg film-coated tablet.	Included on the Grampian Joint Formulary for the indication in question; restricted use	17/11/2015
raltegravir 25mg, 100mg chewable tablets (Isentress®)	1113/15	In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in children from the age of 4 weeks to <2 years. **SMC restriction:** patients who are intolerant or resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) or when these options are compromised due to drug-drug interactions; raltegravir chewable tablets should be prescribed under the supervision of specialists in paediatric HIV. The chewable tablets are not bioequivalent to the film-coated tablets and therefore are not interchangeable.	Included on the Grampian Joint Formulary for the indication in question; restricted use	17/11/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
raltegravir 600mg film-coated tablets (Isentress®)	1280/17	In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and paediatric patients weighing at least 40kg. **SMC restriction:** patients who are intolerant or resistant to non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs) or when these options are compromised due to drug-drug interactions.	Routinely available in line with national guidance, SMC 1280/17 https://www.scottishmedicines.org.uk/media/3122/raltegravir_600mg_isentress_abbreviated_final_oct_2017_for_website.pdf	21/11/2017
ramucirumab 10mg/mL concentrate for solution for infusion (Cyramza®)	1156/16	In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.	Not routinely available as not recommended for use in NHS Scotland, SMC 1156/16 https://www.scottishmedicines.org.uk/media/2211/ramucirumab__cyrmaza__non_sub_final_april_2016_for_website.pdf	17/05/2016
ramucirumab 10mg/mL concentrate for solution for infusion (Cyramza®)	1165/16	In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1165/16 https://www.scottishmedicines.org.uk/media/2212/dad_ramucirumab_cyramza_non-_sub__final_may_2016_for_website.pdf	21/06/2016
ramucirumab 10mg/mL concentrate for solution for infusion (Cyramza®)	1176/16	- In combination with paclitaxel for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy - As monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate	Not routinely available as not recommended for use in NHS Scotland, SMC 1176/16 https://www.scottishmedicines.org.uk/media/2213/ramucirumab_cyramza_non_sub_final_june_2016_for_website.pdf	19/07/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
regorafenib 40mg film-coated tablets (Stivarga®)	1031/15	Treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 21/04/15	16/08/2016
regorafenib 40mg film-coated tablets (Stivarga®)	1118/15	Adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies.	Not recommended for use within NHS Scotland	17/11/2015
reslizumab 10mg/mL concentrate for solution for infusion (Cinqaero®)	1233/17	As add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.	Not routinely available as not recommended for use in NHS Scotland, SMC 1233/17 https://www.scottishmedicines.org.uk/media/3123/reslizumab__cinqaero__resubmission_final_august_2017_for_website.pdf	19/12/2017
Rezolsta® 800mg/150mg film-coated tablets (darunavir/cobicistat)	1081/15	In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 18/08/15	20/10/2015
ribociclib 200mg film-coated tablets (Kisqali®)	1295/18	In combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.	Routinely available in line with national guidance, SMC 1295/18 https://www.scottishmedicines.org.uk/media/3141/ribociclib-kisqali-final-feb-2018-for-website.pdf Updates decision 20/03/18	19/06/2018
rilpivirine 25mg film-coated tablets (Edurant®)	1168/16	In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL.	Routinely available in line with national guidance, SMC 1168/16 https://www.scottishmedicines.org.uk/media/2234/rilpivirine_hydrochloride_edurant_abb_final_july_2016_for_website.pdf	16/08/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
riociguat 0.5mg, 1mg, 1.5mg, 2mg, 2.5mg film-coated tablets (Adempas®)	1056/15	**SMC restriction:** for use as a Pulmonary arterial hypertension (PAH)-specific monotherapy as an alternative treatment option to endothelin receptor antagonist (ERA) monotherapy in adult patients with PAH of WHO FC II to III. It is restricted to initiation and prescribing by specialists in the Scottish Pulmonary Vascular Unit or by similar specialists.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question - because the medication is prescribed and supplied by the National Specialist Centre	21/07/2015
rivaroxaban 2.5mg film-coated tablets (Xarelto®)	1062/15	Rivaroxaban co-administered with aspirin alone or with aspirin plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.	Not recommended for use within NHS Scotland	21/07/2015
roflumilast 500microgram film-coated tablets (Daxas®)	635/10	For maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1]) post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment.	Not routinely available as not recommended for use in NHS Scotland, SMC 635/10 https://www.scottishmedicines.org.uk/media/2261/roflumilast_daxas_resubmission_final_august_2017_for_website.pdf	19/09/2017
rolapitant (as hydrochloride monohydrate) 90mg film-coated tablets (Varuby®)	1266/17	Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy. **SMC restriction:** as a first-line option in adults undergoing highly emetogenic chemotherapy (HEC).	This medicine is now withdrawn from use in the European Union, Updates decision 19/09/17	21/04/2020

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
safinamide 50mg, 100mg film-coated tablets (Xadago®)	1259/17	Treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.	Not routinely available as not recommended for use in NHS Scotland, SMC 1259/17 https://www.scottishmedicines.org.uk/media/2279/safinamide_xadago_non_sub_final_may_2017_for_website.pdf	20/06/2017
secukinumab 150mg pre-filled syringe, pre-filled pen (Cosentyx®)	1054/15	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. **SMC restriction:** for patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 16/06/15	21/07/2015
secukinumab 150mg solution for injection in pre-filled pen and pre-filled syringe (Cosentyx®)	1159/16	Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.	Routinely available in line with national guidance, SMC 1159/16 https://www.scottishmedicines.org.uk/media/2293/secukinumab_cosentyx_final_june_2016_for_website.pdf Updates decision 19/07/16	16/08/2016
secukinumab 150mg solution for injection in pre-filled pen and pre-filled syringe (Cosentyx®)	1167/16	Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. **SMC restriction:** use in patients whose disease has not responded to adequate trials of at least two standard DMARDs either individually or in combination.	Routinely available in line with national guidance, Advice superseded by NICE TA445 Updates decision 16/08/16	18/10/2016
sevelamer carbonate 2.4g powder for oral suspension (Renvela®)	1304/18	Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m^2) with chronic kidney disease. **SMC restriction:** the second-line management of hyperphosphataemia in patients receiving haemodialysis.	Routinely available in line with national guidance, SMC 1304/18 https://www.scottishmedicines.org.uk/media/3124/sevelamer_carbonate_renvela_abbreviated_final_jan_2018_for_website.pdf	20/02/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
sitagliptin 25mg, 50mg, 100mg film-coated tablets (Januvia®)	1083/15	The treatment of type 2 diabetes mellitus to improve glycaemic control in adults as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question, Updates decision 15/09/15	20/10/2015
sofosbuvir 400mg film-coated tablets (Sovaldi®)	1326/18	In combination with other medicinal products for the treatment of chronic hepatitis C in adolescents aged 12 to <18 years.	Not routinely available as not recommended for use in NHS Scotland, SMC 1326/18 https://www.scottishmedicines.org.uk/media/3142/sofosbuvir-solvadi-non-sub-final-feb-2018-for-website.pdf	20/03/2018
sorafenib 200mg film-coated tablets (Nexavar®)	1055/15	Treatment of patients with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine.	Included on the Grampian Joint Formulary for the indication in question; restricted use	21/07/2015
sorafenib 200mg film-coated tablets (Nexavar®)	482/08	The treatment of hepatocellular carcinoma **SMC restriction:** in patients with advanced hepatocellular carcinoma who have failed or are unsuitable for surgical or loco-regional therapies.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 19/01/16	16/08/2016
Spiolto® Respimat® 2.5microgram/2.5microgram inhalation solution (tiotropium/olodaterol)	1099/15	Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).	Included on the Grampian Joint Formulary for the indication in question; pending protocol, Updates decision 17/11/15	16/02/2016
stiripentol 250mg, 500mg hard capsules, 250mg, 500mg powder for oral suspension in sachet (Diacomit®)	524/08	In conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.	Routinely available in line with national guidance, SMC 524/08 https://www.scottishmedicines.org.uk/media/2330/stiripentol_diacomit_resubmission_final_august_2017_for_website.pdf Updates decision 19/09/17	17/10/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Stribild® 150mg/150mg/200mg/245mg film-coated tablets (elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil (as fumarate))	1310/18	Treatment of HIV 1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild® and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.	Not routinely available as not recommended for use in NHS Scotland, ADVICE ARCHIVED	20/02/2018
sucroferric oxyhydroxide 500mg chewable tablets (Velphoro®)	1035/15	For the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD). It should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin D3 or one of its analogues, or calcimimetics to control the development of renal bone disease.	Not included on the Grampian Joint Formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine for the indication in question,	21/04/2015
sufentanil citrate 15micrograms sublingual tablets (Zalviso®)	1270/17	Management of acute moderate to severe post-operative pain in adult patients.	This medicine is now withdrawn from use/discontinued Updates decision 15/08/17	15/08/2023
Symbicort® 200micrograms/6micrograms pressurised inhalation suspension Symbicort Turbohaler® 200micrograms/6micrograms, 400micrograms/6micrograms inhalation powder (budesonide/formoterol)	1198/16	Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.	Not routinely available as not recommended for use in NHS Scotland, SMC 1198/16 https://www.scottishmedicines.org.uk/media/1381/budesonide_formoterol_symbicort_non_sub_final_sept_2016_for_website.pdf	18/10/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Symbicort® SMART® 100micrograms/6micrograms, 200micrograms/6micrograms inhalation powder (budesonide/formoterol)	1244/17	The regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting beta2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" short-acting beta2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting beta2 adrenoceptor agonists.	Routinely available in line with national guidance, SMC 1244/17 https://www.scottishmedicines.org.uk/media/1380/budesonide-formoterol_symbicort_smart_abb_final_may_2017_for_website.pdf Updates decision 20/06/17	21/07/2020
Symtuza® 800mg/150mg/200mg/10mg film-coated tablets (darunavir / cobicistat / emtricitabine / tenofovir alafenamide)	1290/18	For the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).	Routinely available in line with national guidance, SMC 1290/18 https://www.scottishmedicines.org.uk/media/3099/darunavir_symtuza_abbreviated_final_dec_2017_for_website.pdf	16/01/2018
Synjardy® 5mg/85mg, 5mg/1000mg, 12.5mg/850mg, 12.5mg/1000mg film-coated tablets (empagliflozin/metformin)	1092/15	In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control; - in patients inadequately controlled on their maximally tolerated dose of metformin alone - in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin - in patients already being treated with the combination of empagliflozin and metformin as separate tablets. **SMC restriction:** - for use in patients for whom this fixed dose combination of empagliflozin and metformin is considered appropriate. - for use as dual therapy (empagliflozin and metformin) when a sulphonylurea is inappropriate.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question	20/10/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tacrolimus (as monohydrate) 0.75mg, 1mg, 4mg prolonged-release tablets (Envarsus®)	1041/15	Prophylaxis of transplant rejection in adult kidney or liver allograft recipients and treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.	Not included on the Grampian Joint Formulary because clinicians do not support formulary inclusion for this medicine for the indication in question	21/04/2015
talimogene laherparepvec 10^6, 10^8 plaque forming units (PFU)/mL solution for injection (Imlygic®)	1248/17	Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.	Not routinely available as not recommended for use in NHS Scotland, SMC 1248/17 https://www.scottishmedicines.org.uk/media/2358/talimogene_laherparepvec_imlygic_non_sub_final_april_2017_for_website.pdf	20/06/2017
Taptiqom® 15micrograms/mL / 5mg/mL preservative-free eye drops (tafluprost/timolol)	1085/15	Reduction of intraocular pressure in adult patients with open angle glaucoma or ocular hypertension who are insufficiently responsive to topical monotherapy with beta-blockers or prostaglandin analogues and require a combination therapy, and who would benefit from preservative-free eye drops. **SMC restriction:** to use in patients who have proven sensitivity to preservatives.	Not included on the Grampian Joint Formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine for the indication in question	15/09/2015
tedizolid phosphate 200mg film-coated tablets, 200mg powder for concentrate for solution for infusion (Sivextro®)	1080/15	The treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. **SMC restriction:** - use in patients with ABSSSI caused by Gram-positive Staphylococcus aureus (specifically methicillin-resistant Staphylococcus aureus [MRSA] isolates - use of tedizolid phosphate is restricted to use as an alternative oxazolidinone antibacterial on the specific advice of local microbiologists or specialists in infectious disease.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 18/08/15	20/10/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tenofovir alafenamide 25mg film-coated tablets (Vemlidy®)	1238/17	Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35kg).	Not routinely available as not recommended for use in NHS Scotland, SMC 1238/17 https://www.scottishmedicines.org.uk/media/2376/tenofovir_alafenamide_vemlidy_non_sub_final_march_2017_for_website.pdf	18/04/2017
ticagrelor 60mg film-coated tablets (Brilique®)	1224/17	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.	Not routinely available as not recommended for use in NHS Scotland, SMC 1224/17 https://www.scottishmedicines.org.uk/media/2390/ticagrelor_brilique_final_march_2017_for_website.pdf	18/04/2017
tigecycline 50mg powder for solution for infusion (Tygacil®)	1101/15	Treatment in children from the age of eight years for the following infections: - complicated skin and soft tissue infections, excluding diabetic foot infections - complicated intra-abdominal infections	Not recommended for use within NHS Scotland	15/09/2015
tinzaparin 20,000 IU/mL pre-filled syringe (Innohep Syringe®)	1061/15	Patients with solid tumours: extended treatment of symptomatic venous thrombo-embolism (VTE) and prevention of its recurrence.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 21/07/15	15/12/2015
tiotropium 2.5microgram inhalation solution (Spiriva Respimat®)	411/07	As a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).	Routinely available in line with local guidance	19/12/2017
tiotropium 2.5microgram solution for inhalation (Spiriva® Respimat®)	1028/15	As add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥800 micrograms budesonide/day or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year.	Included on the Grampian Joint Formulary for the indication in question; pending protocol, Updates decision 18/08/15	16/02/2016

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
tocilizumab 162mg solution for injection in pre-filled syringe (RoActemra®)	1201/16	Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.	Not routinely available as not recommended for use in NHS Scotland, SMC 1201/16 https://www.scottishmedicines.org.uk/media/2412/tocilizumab_roactemra_non_sub_final_sept_2016_for_website.pdf	18/10/2016
tofacitinib citrate 5mg film-coated tablets (Xeljanz®)	1298/18	In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. **SMC restriction:** in patients with severe disease (a disease activity score [DAS28] greater than 5.1) that has not responded to intensive therapy with a combination of conventional DMARDs. In patients with severe disease inadequately controlled by a tumour necrosis factor (TNF) antagonist, it may be used in patients ineligible to receive rituximab.	Routinely available in line with national guidance, SMC 1298/18 https://www.scottishmedicines.org.uk/media/3126/tofacitinib_xeljanz_final_jan_2018_amended_050217_for_website.pdf Updates decision 20/02/18	17/07/2018
tolvaptan 15mg, 30mg, 45mg, 60mg, 90mg tablets (Jinarc®)	1114/15	To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.	Routinely available in line with national guidance, SMC 1114/15 https://www.scottishmedicines.org.uk/media/2416/tolvaptan_jinarc_final_december_2015_for_website.pdf Updates decision 19/01/16	20/12/2016
trametinib 0.5mg, 2mg film-coated tablets (Mekinist®)	1161/16	In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. **SMC restriction:** to first-line treatment.	Routinely available in line with regional guidance, Updates decision 20/09/16	20/02/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
trametinib 0.5mg, 2mg film-coated tablets (Mekinist®)	1264/17	In combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.	Not routinely available as not recommended for use in NHS Scotland, SMC 1264/17 https://www.scottishmedicines.org.uk/media/2429/trametinib_mekinist_non_submission_final_june_2017_for_website.pdf	18/07/2017
trastuzumab 150mg powder for concentrate for solution for infusion (Herceptin®)	623/10	In combination with capecitabine or fluorouracil and cisplatin for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. It is indicated for use only in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay. **SMC restriction:** for use in patients whose tumours have HER2 overexpression defined by immunohistochemistry (IHC) 3+ ("HER2 high expresser").	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 20/10/15	16/08/2016
trastuzumab emtansine 100mg, 160mg powder for concentrate for solution for infusion (Kadcyla®)	990/14	As a single agent, for the treatment of adult patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: - received prior therapy for locally advanced or metastatic disease, or - developed disease recurrence during or within six months of completing adjuvant therapy	Routinely available in line with national guidance, SMC 990/14 https://www.scottishmedicines.org.uk/media/2436/trastuzumab_emtansine_kadcyla_resub_final_march_2017_for_website.pdf	18/04/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
travoprost 40micrograms/mL eye drops (Travatan®)	1091/15	Decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma.	Not included on the Grampian Joint Formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine for the indication in question	20/10/2015
Trelegy® Ellipta® 92micrograms / 55micrograms / 22micrograms inhalation powder (fluticasone furoate / umeclidinium / vilanterol (as trifenatate))	1303/18	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. **SMC restriction:** in patients with severe COPD (forced expiratory volume in one second [FEV1] <50% predicted normal).	Routinely available in line with local guidance. Use is subject to inclusion in the Respiratory MCN framework for inhaled medicines.	20/02/2018
triamcinolone hexacetonide 20mg/mL suspension for injection	1103/15	Juvenile idiopathic arthritis (JIA).	Included on the Grampian Joint Formulary for the indication in question; restricted use	17/11/2015
Trimbow® 87micrograms / 5micrograms / 9micrograms metered dose inhaler (beclometasone dipropionate /formoterol fumarate dihydrate /glycopyrronium)	1274/17	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. **SMC restriction:** severe COPD (forced expiratory volume in one second less than 50% predicted normal).	Routinely available in line with local guidance. Use is subject to inclusion in the Respiratory MCN framework for inhaled medicines. Updates decision 17/10/17	20/02/2018
Truvada® 200mg/245mg film-coated tablets (emtricitabine/tenofovir disoproxil)	1225/17	In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.	Routinely available in line with national guidance, SMC 1225/17 https://www.scottishmedicines.org.uk/media/1620/emtricitabine_tenofovir_disoproxil_truvada_final_march_2017_for_website.pdf	18/04/2017

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Truvada® 200mg/245mg film-coated tablets (emtricitabine/tenofovir disoproxil)	1263/17	Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents.	Not routinely available as not recommended for use in NHS Scotland, ADVICE ARCHIVED	18/07/2017
ulipristal acetate 5mg tablets (Esmya®)	1128/16	For the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Not routinely available in NHS Grampian. Updates decision 16/02/16	21/12/2021
ustekinumab 130mg concentrate for solution for infusion, 90mg solution for injection (Stelara®)	1250/17	For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist or have medical contraindications to such therapies.	Routinely available in line with national guidance, SMC 1250/17 https://www.scottishmedicines.org.uk/media/2455/ustekinumab_stelara_final_june_2017_for_website.pdf Updates decision 18/07/17	19/09/2017
ustekinumab 45mg solution for injection and prefilled syringe (Stelara®)	1115/15	Treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. **SMC restriction:** continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.	Routinely available in line with national guidance, Advice superseded by NICE TA455 Updates decision 19/01/16	18/07/2017
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®)	1045/15	The treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 19/05/15	17/11/2015

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
vedolizumab 300mg powder for concentrate for solution for infusion (Entyvio®)	1064/15	For the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist. **SMC restriction:** for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to a TNFα antagonist.	Included on the Grampian Joint Formulary for the indication in question; restricted use, Updates decision 21/07/15	17/11/2015
venetoclax 10mg, 50mg, 100mg film-coated tablets (Venclyxto®)	1249/17	As monotherapy for the treatment of chronic lymphocytic leukaemia (CLL): - in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor - in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor	Routinely available in line with national guidance, SMC 1249/17 https://www.scottishmedicines.org.uk/media/2475/venetoclax_venclyxto_final_july_2017_for_website.pdf Updates decision 15/08/17	18/02/2020
vernakalant 20mg/mL concentrate for solution for infusion (Brinavess®)	1222/17	Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: - for non-surgery patients: atrial fibrillation ≤ 7 days duration - for post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration	Not routinely available as not recommended for use in NHS Scotland, SMC 1222/17 https://www.scottishmedicines.org.uk/media/2477/vernakalent_brinavess_non_sub_final_jan_2017_for_website.pdf	21/02/2017
vinflunine (as ditartrate) 25mg/mL concentrate for solution for infusion (Javlor®)	686/11	Monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. Efficacy and safety of vinflunine have not been studied in patients with performance status ≥ 2.	This medicine is now withdrawn from use/discontinued Updates decision 21/07/15	18/10/2022

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
vortioxetine 5mg, 10mg, 20mg film-coated tablets (Brintellix®)	1158/16	The treatment of major depressive episodes in adults. **SMC restriction:** patients who have experienced an inadequate response (either due to lack of adequate efficacy and/or safety concerns/intolerability) to two or more previous antidepressants.	Routinely available in line with national guidance, SMC 1158/16 https://www.scottishmedicines.org.uk/media/2492/vortioxetine_brintellix_final_june_2016_for_website.pdf Updates decision 19/07/16	17/10/2017
Xultophy® 100 units/mL / 3.6mg/mL solution for injection pre-filled pen (insulin degludec/liraglutide)	1088/15	Treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or with basal insulin do not provide adequate glycaemic control. **SMC restriction:** for use in patients who are uncontrolled on basal insulin analogues (glycosylated haemoglobin [HbA1c] >7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin to obtain glucose control.	Not included on the Grampian Joint Formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine for the indication in question	20/10/2015
Zavicefta® 2g/0.5g powder for concentrate for solution for infusion (ceftazidime/avibactam)	1307/18	Treatment of the following infections in adults: - complicated intra-abdominal Infection (cIAI) - complicated urinary tract infection (cUTI), including pyelonephritis - hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) - infections due to aerobic Gram-negative organisms in adult patients with limited treatment options	Not routinely available as not recommended for use in NHS Scotland ADVICE ARCHIVED, replaced by FG advice published 28/11/2022 (FG meeting 15/11/2022).	16/01/2018

Name	Unique identifier	Condition being treated	NHS Grampian decision	Date of decision
Zepatier® 50mg/100mg film-coated tablets (elbasvir/grazoprevir)	1203/17	Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).	Routinely available in line with national guidance, National Clinical Guidelines for the treatment of HCV in adults. https://www.hps.scot.nhs.uk/web-resources-container/national-clinical-guidelines-for-the-treatment-of-hcv-in-adults/	17/01/2017
Zerbaxa® 1g/0.5g powder for concentrate for solution for infusion (ceftolozane/tazobactam)	1146/16	For the treatment of the following infections in adults: - Complicated intra-abdominal infections - Acute pyelonephritis - Complicated urinary tract infections	Not routinely available as not recommended for use in NHS Scotland, SMC 1146/16 https://www.scottishmedicines.org.uk/media/1443/ceftolozane-tazobactam__zerbaxa__final_april_2016_for_website.pdf	17/05/2016